Detection and identification of significant ANAs in previously determined ANA negative samples

Kara Kidd, Karen Cusi, Ruth Mueller, Megan Goodner, Bob Boyes, Eric Hoy

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: An antinuclear antibody (ANA) substrate transfected with the cDNA to hyperexpress the 60 kD SS-A/Ro antigen (HEp-2000®) has been shown to detect anti-SS-A/Ro antibodies missed by standard HEp-2 and other immunoassays. Despite this evidence, many laboratories remain convinced that with experienced technicians, standard HEp-2 is acceptable for ANA detection. Aim: To challenge the ability of HEp-2000® to detect anti-SS-A/Ro antibodies in samples previously determined to be ANA negative using standard HEp-2. Methods: Three hundred and seventy-one pre-screened "negative" ANA samples were provided by a university hospital laboratory in Germany. These samples were tested on the HEp-2000® substrate at a dilution of 1:40 by indirect immunofluorescence (IIF). Samples that screened positive for a nuclear pattern were titered (range of 1:40-1:640) and all ANA-positive patterns were identified. Samples containing at least one positive ANA pattern at a dilution greater than or equal to 1:160 were further tested. Samples that produced a speckled pattern were tested for antibodies to the extractable nuclear antigens (ENA) and samples that showed homogeneous staining were tested for antibodies to dsDNA, and if negative, were then tested for anti-histone antibodies. Results: Ninety-one patient samples were positive with titers ≥1:160. Speckled patterns were the most common finding (30 samples) followed by speckled/homogeneous mixed patterns (19 samples) and samples demonstrating the SS-A/Ro pattern (16 samples) either alone or in combination with other ANA patterns. The remaining 26 positive samples consisted of various other ANA patterns. The most commonly identified ENAs were SS-A/Ro (14 samples), Scl-70 (11 samples) and SSB (6 samples). No antibodies to dsDNA were identified in 23 positive samples with homogeneous staining patterns, though 17 of these samples tested positive for antibodies to histone. Conclusions: HEp-2000® detected anti-SS-A/Ro antibodies in 16 (4%) of the "ANA negative" samples. In addition to improved sensitivity for anti-SS-A antibodies, HEp-2000® demonstrated improved sensitivity over standard HEp-2 substrate for other significant ANAs including anti-Scl-70, anti-histone, and anti-SS-B antibodies.

Original languageEnglish (US)
Pages (from-to)517-521
Number of pages5
JournalClinical Laboratory
Volume51
Issue number9-10
StatePublished - 2005

Fingerprint

Antinuclear Antibodies
Antibodies
Histones
Dilution
Substrates
Staining and Labeling
Hospital Laboratories
Nuclear Antigens
Indirect Fluorescent Antibody Technique
SS-A antibodies
Immunoassay
Germany
Anti-Idiotypic Antibodies
Complementary DNA

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Kidd, K., Cusi, K., Mueller, R., Goodner, M., Boyes, B., & Hoy, E. (2005). Detection and identification of significant ANAs in previously determined ANA negative samples. Clinical Laboratory, 51(9-10), 517-521.

Detection and identification of significant ANAs in previously determined ANA negative samples. / Kidd, Kara; Cusi, Karen; Mueller, Ruth; Goodner, Megan; Boyes, Bob; Hoy, Eric.

In: Clinical Laboratory, Vol. 51, No. 9-10, 2005, p. 517-521.

Research output: Contribution to journalArticle

Kidd, K, Cusi, K, Mueller, R, Goodner, M, Boyes, B & Hoy, E 2005, 'Detection and identification of significant ANAs in previously determined ANA negative samples', Clinical Laboratory, vol. 51, no. 9-10, pp. 517-521.
Kidd K, Cusi K, Mueller R, Goodner M, Boyes B, Hoy E. Detection and identification of significant ANAs in previously determined ANA negative samples. Clinical Laboratory. 2005;51(9-10):517-521.
Kidd, Kara ; Cusi, Karen ; Mueller, Ruth ; Goodner, Megan ; Boyes, Bob ; Hoy, Eric. / Detection and identification of significant ANAs in previously determined ANA negative samples. In: Clinical Laboratory. 2005 ; Vol. 51, No. 9-10. pp. 517-521.
@article{6c74be4769be4aaa955f26d9e77a3487,
title = "Detection and identification of significant ANAs in previously determined ANA negative samples",
abstract = "Background: An antinuclear antibody (ANA) substrate transfected with the cDNA to hyperexpress the 60 kD SS-A/Ro antigen (HEp-2000{\circledR}) has been shown to detect anti-SS-A/Ro antibodies missed by standard HEp-2 and other immunoassays. Despite this evidence, many laboratories remain convinced that with experienced technicians, standard HEp-2 is acceptable for ANA detection. Aim: To challenge the ability of HEp-2000{\circledR} to detect anti-SS-A/Ro antibodies in samples previously determined to be ANA negative using standard HEp-2. Methods: Three hundred and seventy-one pre-screened {"}negative{"} ANA samples were provided by a university hospital laboratory in Germany. These samples were tested on the HEp-2000{\circledR} substrate at a dilution of 1:40 by indirect immunofluorescence (IIF). Samples that screened positive for a nuclear pattern were titered (range of 1:40-1:640) and all ANA-positive patterns were identified. Samples containing at least one positive ANA pattern at a dilution greater than or equal to 1:160 were further tested. Samples that produced a speckled pattern were tested for antibodies to the extractable nuclear antigens (ENA) and samples that showed homogeneous staining were tested for antibodies to dsDNA, and if negative, were then tested for anti-histone antibodies. Results: Ninety-one patient samples were positive with titers ≥1:160. Speckled patterns were the most common finding (30 samples) followed by speckled/homogeneous mixed patterns (19 samples) and samples demonstrating the SS-A/Ro pattern (16 samples) either alone or in combination with other ANA patterns. The remaining 26 positive samples consisted of various other ANA patterns. The most commonly identified ENAs were SS-A/Ro (14 samples), Scl-70 (11 samples) and SSB (6 samples). No antibodies to dsDNA were identified in 23 positive samples with homogeneous staining patterns, though 17 of these samples tested positive for antibodies to histone. Conclusions: HEp-2000{\circledR} detected anti-SS-A/Ro antibodies in 16 (4{\%}) of the {"}ANA negative{"} samples. In addition to improved sensitivity for anti-SS-A antibodies, HEp-2000{\circledR} demonstrated improved sensitivity over standard HEp-2 substrate for other significant ANAs including anti-Scl-70, anti-histone, and anti-SS-B antibodies.",
author = "Kara Kidd and Karen Cusi and Ruth Mueller and Megan Goodner and Bob Boyes and Eric Hoy",
year = "2005",
language = "English (US)",
volume = "51",
pages = "517--521",
journal = "Clinical Laboratory",
issn = "1433-6510",
publisher = "Verlag Klinisches Labor GmbH",
number = "9-10",

}

TY - JOUR

T1 - Detection and identification of significant ANAs in previously determined ANA negative samples

AU - Kidd, Kara

AU - Cusi, Karen

AU - Mueller, Ruth

AU - Goodner, Megan

AU - Boyes, Bob

AU - Hoy, Eric

PY - 2005

Y1 - 2005

N2 - Background: An antinuclear antibody (ANA) substrate transfected with the cDNA to hyperexpress the 60 kD SS-A/Ro antigen (HEp-2000®) has been shown to detect anti-SS-A/Ro antibodies missed by standard HEp-2 and other immunoassays. Despite this evidence, many laboratories remain convinced that with experienced technicians, standard HEp-2 is acceptable for ANA detection. Aim: To challenge the ability of HEp-2000® to detect anti-SS-A/Ro antibodies in samples previously determined to be ANA negative using standard HEp-2. Methods: Three hundred and seventy-one pre-screened "negative" ANA samples were provided by a university hospital laboratory in Germany. These samples were tested on the HEp-2000® substrate at a dilution of 1:40 by indirect immunofluorescence (IIF). Samples that screened positive for a nuclear pattern were titered (range of 1:40-1:640) and all ANA-positive patterns were identified. Samples containing at least one positive ANA pattern at a dilution greater than or equal to 1:160 were further tested. Samples that produced a speckled pattern were tested for antibodies to the extractable nuclear antigens (ENA) and samples that showed homogeneous staining were tested for antibodies to dsDNA, and if negative, were then tested for anti-histone antibodies. Results: Ninety-one patient samples were positive with titers ≥1:160. Speckled patterns were the most common finding (30 samples) followed by speckled/homogeneous mixed patterns (19 samples) and samples demonstrating the SS-A/Ro pattern (16 samples) either alone or in combination with other ANA patterns. The remaining 26 positive samples consisted of various other ANA patterns. The most commonly identified ENAs were SS-A/Ro (14 samples), Scl-70 (11 samples) and SSB (6 samples). No antibodies to dsDNA were identified in 23 positive samples with homogeneous staining patterns, though 17 of these samples tested positive for antibodies to histone. Conclusions: HEp-2000® detected anti-SS-A/Ro antibodies in 16 (4%) of the "ANA negative" samples. In addition to improved sensitivity for anti-SS-A antibodies, HEp-2000® demonstrated improved sensitivity over standard HEp-2 substrate for other significant ANAs including anti-Scl-70, anti-histone, and anti-SS-B antibodies.

AB - Background: An antinuclear antibody (ANA) substrate transfected with the cDNA to hyperexpress the 60 kD SS-A/Ro antigen (HEp-2000®) has been shown to detect anti-SS-A/Ro antibodies missed by standard HEp-2 and other immunoassays. Despite this evidence, many laboratories remain convinced that with experienced technicians, standard HEp-2 is acceptable for ANA detection. Aim: To challenge the ability of HEp-2000® to detect anti-SS-A/Ro antibodies in samples previously determined to be ANA negative using standard HEp-2. Methods: Three hundred and seventy-one pre-screened "negative" ANA samples were provided by a university hospital laboratory in Germany. These samples were tested on the HEp-2000® substrate at a dilution of 1:40 by indirect immunofluorescence (IIF). Samples that screened positive for a nuclear pattern were titered (range of 1:40-1:640) and all ANA-positive patterns were identified. Samples containing at least one positive ANA pattern at a dilution greater than or equal to 1:160 were further tested. Samples that produced a speckled pattern were tested for antibodies to the extractable nuclear antigens (ENA) and samples that showed homogeneous staining were tested for antibodies to dsDNA, and if negative, were then tested for anti-histone antibodies. Results: Ninety-one patient samples were positive with titers ≥1:160. Speckled patterns were the most common finding (30 samples) followed by speckled/homogeneous mixed patterns (19 samples) and samples demonstrating the SS-A/Ro pattern (16 samples) either alone or in combination with other ANA patterns. The remaining 26 positive samples consisted of various other ANA patterns. The most commonly identified ENAs were SS-A/Ro (14 samples), Scl-70 (11 samples) and SSB (6 samples). No antibodies to dsDNA were identified in 23 positive samples with homogeneous staining patterns, though 17 of these samples tested positive for antibodies to histone. Conclusions: HEp-2000® detected anti-SS-A/Ro antibodies in 16 (4%) of the "ANA negative" samples. In addition to improved sensitivity for anti-SS-A antibodies, HEp-2000® demonstrated improved sensitivity over standard HEp-2 substrate for other significant ANAs including anti-Scl-70, anti-histone, and anti-SS-B antibodies.

UR - http://www.scopus.com/inward/record.url?scp=27844495168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27844495168&partnerID=8YFLogxK

M3 - Article

VL - 51

SP - 517

EP - 521

JO - Clinical Laboratory

JF - Clinical Laboratory

SN - 1433-6510

IS - 9-10

ER -